Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents. Othman TA, Mei M, Zhang J, Aldoss I, et al. Am J Hematol 2021;96:E140-E143.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Othman TA, Mei M, Zhang J, Aldoss I, et al. Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents. Am J Hematol 2021;96:E140-E143.
PMID: 33524204